CAMBRIDGE, Mass.--(BUSINESS WIRE)--C4 Therapeutics (C4T) today announced it has appointed Ron Kaiser as Chief Financial Officer. Ron has more than three decades of extensive executive management and financial leadership experience in financial reporting, funding and growth management. He also served on C4T’s Board of Directors from January 2016 until October 2017.
Over a span of 35 years, Ron has led six companies through IPO funding in multiple roles, including Chief Financial Officer and Treasurer, and helped manage dozens of major business transactions. He has served as a board member for several public and private entities. Ron holds B.A. degrees in Accounting and Social Science from Michigan State University. At C4T, Ron will be responsible for finance functions and play a central role in the Company’s growth plans, for partners and C4T’s internal pipeline, as the Company brings forward novel drugs based on Targeted Protein Degradation (TPD).
“We are excited that Ron is joining C4T’s management team at this stage of our growth,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Ron’s extensive background in public and private funding, as well as his business knowledge in establishing successful partnerships and preparing companies for growth, will bring much to our development plans over the next several years. We are all looking forward to working with him in this newly established role.”
About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4T’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.